1. Home
  2. GKOS vs PDFS Comparison

GKOS vs PDFS Comparison

Compare GKOS & PDFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • PDFS
  • Stock Information
  • Founded
  • GKOS 1998
  • PDFS 1992
  • Country
  • GKOS United States
  • PDFS United States
  • Employees
  • GKOS N/A
  • PDFS N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • PDFS EDP Services
  • Sector
  • GKOS Health Care
  • PDFS Technology
  • Exchange
  • GKOS Nasdaq
  • PDFS Nasdaq
  • Market Cap
  • GKOS 5.1B
  • PDFS 668.1M
  • IPO Year
  • GKOS 2015
  • PDFS N/A
  • Fundamental
  • Price
  • GKOS $90.36
  • PDFS $18.54
  • Analyst Decision
  • GKOS Strong Buy
  • PDFS Strong Buy
  • Analyst Count
  • GKOS 13
  • PDFS 3
  • Target Price
  • GKOS $135.15
  • PDFS $33.33
  • AVG Volume (30 Days)
  • GKOS 1.1M
  • PDFS 205.0K
  • Earning Date
  • GKOS 04-30-2025
  • PDFS 05-08-2025
  • Dividend Yield
  • GKOS N/A
  • PDFS N/A
  • EPS Growth
  • GKOS N/A
  • PDFS 25.00
  • EPS
  • GKOS N/A
  • PDFS 0.10
  • Revenue
  • GKOS $404,523,000.00
  • PDFS $179,465,000.00
  • Revenue This Year
  • GKOS $27.84
  • PDFS $18.10
  • Revenue Next Year
  • GKOS $27.88
  • PDFS $18.98
  • P/E Ratio
  • GKOS N/A
  • PDFS $191.00
  • Revenue Growth
  • GKOS 23.92
  • PDFS 8.22
  • 52 Week Low
  • GKOS $77.10
  • PDFS $15.91
  • 52 Week High
  • GKOS $163.71
  • PDFS $39.70
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 47.66
  • PDFS 51.04
  • Support Level
  • GKOS $84.26
  • PDFS $18.60
  • Resistance Level
  • GKOS $92.27
  • PDFS $19.89
  • Average True Range (ATR)
  • GKOS 3.86
  • PDFS 0.79
  • MACD
  • GKOS 0.66
  • PDFS 0.26
  • Stochastic Oscillator
  • GKOS 65.16
  • PDFS 69.62

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About PDFS PDF Solutions Inc.

PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.

Share on Social Networks: